Investment analysts at StockNews.com initiated coverage on shares of Endo International (NASDAQ:ENDP – Get Rating) (TSE:ENL) in a research report issued on Saturday. The firm set a "hold" rating on the stock.
A number of other equities analysts have also commented on ENDP. BMO Capital Markets reduced their price target on shares of Endo International from $4.00 to $2.00 in a research report on Monday, May 9th. Piper Sandler downgraded shares of Endo International from a "neutral" rating to an "underweight" rating and lowered their target price for the company from $3.00 to $1.00 in a research note on Friday, May 6th. Finally, Barclays reduced their price target on shares of Endo International from $2.00 to $1.00 in a report on Monday, May 9th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and one has assigned a buy rating to the company's stock. According to MarketBeat, Endo International has an average rating of "Hold" and an average price target of $2.50.
Get Endo International alerts:
Endo International Trading Down 5.0 %
Endo International stock opened at $0.29 on Friday. The company has a market capitalization of $68.80 million, a P/E ratio of -0.03 and a beta of 1.15. Endo International has a 1-year low of $0.28 and a 1-year high of $7.07. The firm's fifty day simple moving average is $0.45 and its 200-day simple moving average is $1.38.
Institutional Investors Weigh In On Endo International
Several hedge funds have recently added to or reduced their stakes in the business. NorthCrest Asset Manangement LLC bought a new stake in Endo International during the 1st quarter valued at $28,000. First Quadrant LLC CA purchased a new stake in Endo International during the first quarter valued at about $36,000. Campbell & CO Investment Adviser LLC purchased a new stake in Endo International during the fourth quarter valued at about $68,000. Carolina Wealth Advisors LLC increased its position in shares of Endo International by 20.2% during the first quarter. Carolina Wealth Advisors LLC now owns 29,862 shares of the company's stock valued at $69,000 after buying an additional 5,028 shares during the period. Finally, Sterling Investment Advisors Ltd. increased its position in shares of Endo International by 36.3% during the first quarter. Sterling Investment Advisors Ltd. now owns 37,515 shares of the company's stock valued at $87,000 after buying an additional 10,000 shares during the period. 80.39% of the stock is currently owned by institutional investors and hedge funds.
About Endo International
(Get Rating)
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology.